文献速递关节外科创伤骨科

直接前入路全髋关节置换术后异位骨化:术后镇痛用与不用非甾体抗炎药的对比

Heterotopic Ossification Following Direct Anterior Total Hip Arthroplasty With and Without Postoperative Analgesic Nonsteroidal Anti-inflammatories.
PubMed 文献 · J Arthroplasty · 2021-05-19

该回顾性研究纳入688例单术者直接前入路全髋关节置换术,比较出院后服用塞来昔布3周与否对异位骨化(HO)的影响。结果显示总体HO发生率为9.6%,未用药组HO率为14.3%,用药组为4.3%,用药组显著降低HO形成。

要点

  • 直接前入路全髋置换术后HO总体发生率为9.6%。
  • 未用塞来昔布组HO率14.3%,用药组仅4.3%。
  • 严重HO(Booker≥3级)用药组0.3%,对照组2.2%。

核心结论

  • 术后镇痛使用塞来昔布可显著降低直接前入路全髋关节置换术后异位骨化的形成。

研究设计与样本

  • 回顾性查询2013至2020年由单一术者完成的直接前入路全髋关节置换术,按出院后是否服用塞来昔布3周分组。

主要发现

  • 共纳入688例直接前入路全髋关节置换术,异位骨化总体发生率为9.6%(n=66)。
  • Booker分级1级5.7%(n=39)、2级2.6%(n=18)、3级1.2%(n=8)、4级0.1%(n=1)。

关键数值与推荐

  • 异位骨化采用Brooker分类系统评估,基于术前及术后2周、6周、3个月、1年X线片。
  • 塞来昔布用法为出院后服用3周。

临床怎么用

  • 可将术后短期塞来昔布作为多模式镇痛方案的一部分,以降低直接前入路全髋置换术后异位骨化风险。

局限性

  • 本研究为回顾性设计,需未来前瞻性随机研究确定理想剂量、疗程和剂型。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Heterotopic ossification (HO) can result in poorer clinical outcomes following total hip arthroplasty (THA). Multiple modes of intervention have been evaluated for HO prevention, including the use of nonsteroidal anti-inflammatories. Additionally, multimodal pain management strategies including celecoxib have become more prominent. Therefore, this study aims to evaluate the influence of celecoxib as part of postoperative analgesia on the risk of developing HO following the direct anterior approach (DA) for THA. METHODS: A retrospective query identified primary DA THAs performed by a single surgeon between 2013 and 2020. Patients were grouped according to those who received 3 weeks celecoxib upon discharge, and those who did not. Radiographs were used to categorize patients according to the Brooker classification system for HO. Preoperative and 2-week, 6-week, 3-month, and 1-year postoperative X-rays were evaluated. RESULTS: A total of 688 DA THAs were included, demonstrating a 9.6% (n = 66) incidence of HO with Brooker classification: 1: 5.7% (n = 39); 2: 2.6% (n = 18); 3: 1.2% (n = 8); and 4: 0.1% (n = 1). Patients who did not receive celecoxib had a 14.3% (52/364) rate of HO following THA (odds ratio 4.53, P < .001) vs only 4.3% (14/324) in the celecoxib group (odds ratio 0.22, P < .001). Overall, 9 patients (1.3%) went on to develop significant HO (Booker 3 or greater): 8 (2.2%) in the control group and 1 (0.3%) in the celecoxib group (P < .001). CONCLUSION: Our findings suggest a significant reduction in the formation of HO following DA THA when using postoperative analgesic celecoxib as part of a multimodal pain protocol. Future prospective randomized studies are needed to identify ideal dosage, duration, and formulation to reduce the risk of HO while optimizing multimodal pain management.

来源:J Arthroplasty,查看原文。版权归原作者所有。

引用

  1. Naylor BH, Iturriaga CR, Bisen YB, et al. Heterotopic Ossification Following Direct Anterior Total Hip Arthroplasty With and Without Postoperative Analgesic Nonsteroidal Anti-inflammatories. J Arthroplasty. 2021. PMID: 34130870. doi:10.1016/j.arth.2021.05.017

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。